Weekly Analysts’ Ratings Changes for Penumbra (PEN)

Several analysts have recently updated their ratings and price targets for Penumbra (NYSE: PEN):

• 11/6/2025 – Penumbra had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $286.00 price target on the stock.
• 11/6/2025 – Penumbra had its price target raised by analysts at Canaccord Genuity Group Inc. from $350.00 to $355.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Penumbra had its price target raised by analysts at JPMorgan Chase & Co. from $265.00 to $275.00. They now have a “neutral” rating on the stock.
• 11/1/2025 – Penumbra was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 10/27/2025 – Penumbra had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $320.00 price target on the stock.
• 10/27/2025 – Penumbra had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $326.00 price target on the stock.
• 10/15/2025 – Penumbra had its price target lowered by analysts at Truist Financial Corporation from $310.00 to $300.00. They now have a “buy” rating on the stock.
• 10/11/2025 – Penumbra was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 10/8/2025 – Penumbra was given a new $326.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
• 10/8/2025 – Penumbra was upgraded by analysts at Needham & Company LLC from a “hold” rating to a “buy” rating. They now have a $326.00 price target on the stock.
• 10/8/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – Penumbra had its price target lowered by analysts at Evercore ISI from $300.00 to $285.00. They now have an “outperform” rating on the stock.
• 10/1/2025 – Penumbra was given a new $290.00 price target on by analysts at Wells Fargo & Company.
• 9/27/2025 – Penumbra had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Penumbra was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Insider Transactions at Penumbra

In other Penumbra news, CEO Adam Elsesser sold 15,800 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $269.65, for a total value of $4,260,470.00. Following the transaction, the chief executive officer owned 182,460 shares of the company’s stock, valued at $49,200,339. This represents a 7.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Harpreet Grewal sold 186 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total transaction of $42,329.88. Following the transaction, the director directly owned 8,516 shares of the company’s stock, valued at approximately $1,938,071.28. This trade represents a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 48,802 shares of company stock valued at $12,588,928. 4.20% of the stock is currently owned by company insiders.

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.